ReviewBioMed research international2013
Aspergillus-associated airway disease, inflammation, and the innate immune response.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.The Cochrane database of systematic reviews · 2019Pooled it
- Pooled it
- Pulmonary Aspergillus Nodule in an Immunocompetent Host: A Case Report.Clinical case reports · 2026Article
- Article
- Effect of transientERJ open research · 2026Article
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- The hyphae-specific CmSphere · 2025Article
- Massive hemoptysis due to pulmonary artery pseudoaneurysm in invasive aspergillosis in a patient with interstitial lung disease and suspected Aspergillioma: A case report.Respiratory medicine case reports · 2025Article
- Genome-wide patterns of noncoding and protein-coding sequence variation in the major fungal pathogen Aspergillus fumigatus.G3 (Bethesda, Md.) · 2024Article
- A Rare Case of Invasive Thyroid Aspergillosis Revealed onDiagnostics (Basel, Switzerland) · 2024Article
- The Precision Medicine Era of Bronchiectasis.American journal of respiratory and critical care medicine · 2024Article
- Characterization ofJournal of medical microbiology · 2024Article
- Genome-wide patterns of non-coding sequence variation in the major fungal pathogenbioRxiv : the preprint server for biology · 2024Article
- Accelerating the understanding ofCurrent research in microbial sciences · 2024Review
- Infection, Allergy, and Inflammation: The Role ofMicroorganisms · 2023Review
- Article
- Protective role of CFTR during fungal infection of cystic fibrosis bronchial epithelial cells withFrontiers in cellular and infection microbiology · 2023Article
- Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease.Frontiers in microbiology · 2023Article
- Sensitisation to recombinantThe European respiratory journal · 2023Article
- Anti-Aspergillus fumigatus IgG in patients with bronchiectasis and its relationship with clinical outcome.Archives of microbiology · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus moulds exist ubiquitously as spores that are inhaled in large numbers daily. Whilst most are removed by anatomical barriers, disease may occur in certain circumstances. Depending on the underlying state of the human immune system, clinical consequences can ensue ranging from an excessive immune response during allergic bronchopulmonary aspergillosis to the formation of an aspergilloma in the immunocompetent state. The severest infections occur in those who are immunocompromised where invasive pulmonary aspergillosis results in high mortality rates. The diagnosis of Aspergillus-associated pulmonary disease is based on clinical, radiological, and immunological testing. An understanding of the innate and inflammatory consequences of exposure to Aspergillus species is critical in accounting for disease manifestations and preventing sequelae. The major components of the innate immune system involved in recognition and removal of the fungus include phagocytosis, antimicrobial peptide production, and recognition by pattern recognition receptors. The cytokine response is also critical facilitating cell-to-cell communication and promoting the initiation, maintenance, and resolution of the host response. In the following review, we discuss the above areas with a focus on the innate and inflammatory response to airway Aspergillus exposure and how these responses may be modulated for therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.